microarray gene expression profiles dasl (Illumina Inc)
Illumina Inc is a verified supplier 
90
Structured Review
Illumina Inc
microarray gene expression profiles dasl
Microarray Gene Expression Profiles Dasl, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+gene+expression+profiles/daslmicroarray+platform/pm37531111-31-23-28
Average 90 stars, based on 1 article reviews
Microarray Gene Expression Profiles Dasl, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+gene+expression+profiles/daslmicroarray+platform/pm37531111-31-23-28
Average 90 stars, based on 1 article reviews
microarray gene expression profiles dasl - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Expressing:Article Title: Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review Article Snippet: .. This study used expression data ( Article Title: Tumour gene expression signature in primary melanoma predicts long-term outcomes Article Snippet: .. 2. partial vs genome-wide expression data: As discussed more thoroughly in the next question, the LMC, Gerami and Lund datasets were generated using Multiple Displacement Amplification:Article Title: Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review Article Snippet: .. This study used expression data ( other:Article Title: Prognostic stratification in DLBCL patients with aberrant MYC gene. Article Snippet: Diffuse large Bcell lymphoma (DLBCL), the most common type of nonHodgkin's lymphoma, is an aggressive cancer that arises from B cells.. Treatment with a rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone regimen (RCHOP) has been the therapeutic standard for almost 20 years, achieving a cure in 50%–70% of patients.1 Although many patients with DLBCL have favourable disease outcomes and experience remission with firstline therapy, nearly half of all patients experience disease progression, and approximately 25% of DLBCL patients die from their illness.2 Of the ~40% of patients who experience refractory disease after treatment or disease relapse, around 80% will ultimately die from lymphoma, despite further treatment with salvage chemotherapy or autologous stem cell transplantation (ASCT).3 In recent years, research efforts in the field have focused on improving the RCHOP regimen, including newer regimens such as DAREPOCH (doseadjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin), and personalized therapy is especially important for patients with highrisk tumour genetics or poor prognostic markers.1 DLBCL is a highly heterogeneous disease with appreciated biological, pathological and clinical variability O R I G I N A L P A P E R Microarray:Article Title: Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. Article Snippet: .. We integrated data sets from 2 independent ancillary analyses of ICON7 by Kommoss et al17 and Desbois et al.18 We obtained Article Title: Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. Article Snippet: .. ICON7-A Cohort We integrated data sets from 2 independent ancillary analyses of ICON7 by Kommoss et al17 and Desbois et al.18 We obtained Gene Expression:Article Title: Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. Article Snippet: .. We integrated data sets from 2 independent ancillary analyses of ICON7 by Kommoss et al17 and Desbois et al.18 We obtained Article Title: Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer. Article Snippet: .. ICON7-A Cohort We integrated data sets from 2 independent ancillary analyses of ICON7 by Kommoss et al17 and Desbois et al.18 We obtained Genome Wide:Article Title: Tumour gene expression signature in primary melanoma predicts long-term outcomes Article Snippet: .. 2. partial vs genome-wide expression data: As discussed more thoroughly in the next question, the LMC, Gerami and Lund datasets were generated using Generated:Article Title: Tumour gene expression signature in primary melanoma predicts long-term outcomes Article Snippet: .. 2. partial vs genome-wide expression data: As discussed more thoroughly in the next question, the LMC, Gerami and Lund datasets were generated using Article Title: Tumour gene expression signature in primary melanoma predicts long-term outcomes Article Snippet: .. In particular, it is important to recognize that the LMC, Gerami and Lund datasets were generated using an RNA Sequencing:Article Title: Tumour gene expression signature in primary melanoma predicts long-term outcomes Article Snippet: .. 2. partial vs genome-wide expression data: As discussed more thoroughly in the next question, the LMC, Gerami and Lund datasets were generated using Article Title: Tumour gene expression signature in primary melanoma predicts long-term outcomes Article Snippet: .. In particular, it is important to recognize that the LMC, Gerami and Lund datasets were generated using an RNA Extraction:Article Title: Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Article Snippet: Objective: Platinum-based chemotherapy plus the anti-EGFR monoclonal antibody (mAb) cetuximab is used to treat recurrent/metastatic (RM) head-neck squamous cell carcinoma (HNSCC).. Recently, we defined Cluster3 gene-expression signature as a potential predictor of favorable progression-free survival (PFS) in cetuximabtreated RM-HNSCC patients and predictor of partial metabolic FDG-PET response in an afatinib window-ofopportunity trial.. Another anti-EGFR-mAb (panitumumab) was used as the treatment agent in RM-HNSCC patients in the phase II PANI01trial. Control:Article Title: Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Article Snippet: Objective: Platinum-based chemotherapy plus the anti-EGFR monoclonal antibody (mAb) cetuximab is used to treat recurrent/metastatic (RM) head-neck squamous cell carcinoma (HNSCC).. Recently, we defined Cluster3 gene-expression signature as a potential predictor of favorable progression-free survival (PFS) in cetuximabtreated RM-HNSCC patients and predictor of partial metabolic FDG-PET response in an afatinib window-ofopportunity trial.. Another anti-EGFR-mAb (panitumumab) was used as the treatment agent in RM-HNSCC patients in the phase II PANI01trial. Hybridization:Article Title: Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Article Snippet: Objective: Platinum-based chemotherapy plus the anti-EGFR monoclonal antibody (mAb) cetuximab is used to treat recurrent/metastatic (RM) head-neck squamous cell carcinoma (HNSCC).. Recently, we defined Cluster3 gene-expression signature as a potential predictor of favorable progression-free survival (PFS) in cetuximabtreated RM-HNSCC patients and predictor of partial metabolic FDG-PET response in an afatinib window-ofopportunity trial.. Another anti-EGFR-mAb (panitumumab) was used as the treatment agent in RM-HNSCC patients in the phase II PANI01trial. |
